Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Part D vs. Obamacare Roll-Out: The Comparisons Continue

This article was originally published in RPM Report

Executive Summary

The Part D rollout is not a perfect parallel for the launch of the Affordable Care Act, but comparing their respective “glitches” is now commonplace. Former CMS Administrator Mark McClellan sees important differences—and cautions that the toughest test is still to come.

You may also be interested in...



Confusion Marks Rollout Of Universal Health Coverage In Indonesia

Initial confusion on access, eligibility and paperwork greeted the rollout of phased national health insurance for Indonesia that aims to achieve a nationwide footprint before the end of the decade.

Part D and the Exchanges: Not A Perfect Analogy

In the run up to its launch in 2006, Part D was politically controversial and there was considerable skepticism about the logistical challenges for implementation. That experience is reassuring for implementers of the Affordable Care Act – but advocates should be wary of relying too much on parallels to Part D.

MedPAC’s Message To Congress: Drug Pricing Still Needs Attention

The US Medicare Payment Advisory Commission is continuing its work on proposals to overhaul federal payment for physician administered drugs. That is an ominous message for the biopharma industry as it reels from passage of dramatic pricing legislation earlier this year.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS081076

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel